Related Experiment Videos
Agranulocytosis and chlorpromazine
The Journal of Clinical Psychiatry
|October 1, 1978
Summary
Chlorpromazine can cause agranulocytosis, a dangerous drop in white blood cells, particularly in elderly, frail Caucasian women. Monitoring medication, cumulative dose, and infection signs can help prevent this serious side effect.
Area of Science:
- Pharmacology
- Hematology
- Toxicology
Background:
- Chlorpromazine is an antipsychotic medication with known risks.
- Agranulocytosis is a severe adverse effect characterized by a significant reduction in neutrophils.
- Understanding risk factors is crucial for patient safety.
Observation:
- This case report details a death linked to chlorpromazine-induced agranulocytosis.
- A review of existing literature on chlorpromazine agranulocytosis was conducted.
Findings:
- The risk of chlorpromazine agranulocytosis is associated with the cumulative dose administered.
- Elderly, debilitated Caucasian females represent a high-risk demographic for this adverse event.
Implications:
- Regularly assessing the necessity of chlorpromazine treatment is recommended.
- Close monitoring of cumulative dosage and early detection of infection or fever are vital.
- Proactive patient management can potentially decrease the incidence of chlorpromazine-induced agranulocytosis.